Andra AP fonden Acquires 30,900 Shares of Solventum Corporation $SOLV

Key Points

• Andra AP fonden increased its Solventum stake by 55.5% in the first quarter, buying 30,900 additional shares and bringing its total holdings to 86,615 shares worth about $5.66 million.
• Other major institutional investors also boosted positions in Solventum, including Independent Franchise Partners, State Street, Davis Selected Advisers, Boston Partners, and Geode Capital Management.
• Wall Street is mixed on Solventum: the stock has a Hold consensus rating with an average target price of $81.91, while recent earnings beat estimates and the shares were trading around $77.76.

Andra AP fonden raised its holdings in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 55.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,615 shares of the company's stock after purchasing an additional 30,900 shares during the quarter. Andra AP fonden owned 0.05% of Solventum worth $5,656,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Independent Franchise Partners LLP boosted its holdings in shares of Solventum by 19.0% in the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company's stock worth $1,216,785,000 after purchasing an additional 2,456,451 shares during the period. State Street Corp boosted its stake in Solventum by 2.0% during the fourth quarter. State Street Corp now owns 6,344,761 shares of the company's stock worth $502,759,000 after buying an additional 124,490 shares during the period. Davis Selected Advisers increased its position in Solventum by 12.7% during the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company's stock valued at $492,880,000 after acquiring an additional 702,461 shares during the last quarter. Boston Partners raised its stake in shares of Solventum by 26.1% in the third quarter. Boston Partners now owns 4,630,300 shares of the company's stock valued at $338,006,000 after acquiring an additional 959,543 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Solventum by 20.0% in the fourth quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company's stock valued at $362,375,000 after acquiring an additional 763,308 shares during the period.

Wall Street Analyst Weigh In

Several analysts have issued reports on SOLV shares. Weiss Ratings raised shares of Solventum from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, July 17th. Wells Fargo & Company decreased their price target on Solventum from $83.00 to $70.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 6th. BTIG Research restated a "buy" rating and set a $91.00 price objective on shares of Solventum in a report on Monday, July 13th. BMO Capital Markets initiated coverage on Solventum in a research report on Wednesday, July 8th. They issued a "market perform" rating and a $81.00 price objective on the stock. Finally, KeyCorp increased their target price on Solventum from $92.00 to $93.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $81.91.

Solventum Trading Down 1.1%

SOLV opened at $77.76 on Thursday. The stock's fifty day moving average is $77.33 and its two-hundred day moving average is $74.21. The company has a market capitalization of $13.47 billion, a P/E ratio of 9.53, a PEG ratio of 1.21 and a beta of 0.66. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $88.20. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. Solventum's revenue was down 3.0% on a year-over-year basis. During the same period last year, the firm posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.